![]() |
|
MICA Rather Than MICB, TNFA, or HLA-DRB1 Is Associated with Susceptibility to Psoriatic Arthritis
SEGUNDO GONZÁLEZ, JESÚS MARTÍNEZ-BORRA, ANTONIO LÓPEZ-VÁZQUEZ, SONIA GARCÍA-FERNÁNDEZ, JUAN CARLOS TORRE-ALONSO, and CARLOS LÓPEZ-LARREA
ABSTRACT. Methods. DNA samples from 81 Spanish patients with PsA and 110 healthy controls were examined by polymerase chain reaction (PCR) sequence-specific primers to type HLA-Cw and HLA-DRB1, PCR sequence-specific oligonucleotides to determine HLA-B, and PCR restriction fragment length polymorphism for tumor necrosis factor-a promoter polymorphisms at positions -238 and -308. Analysis of microsatellite polymorphisms in the transmembrane region of MICA and in intron 1 of MICB was also carried out. Results. HLA-Cw*0602 was significantly increased in PsA [60% vs 17%; pc < 0.00002, OR 7.33, etiological fraction (EF) 0.52]. MICA-A9 (60% vs 30%; pc = 0.0002, OR 3.57, EF 0.43) and the microsatellite MICB-CA-22 allele (23% vs 7%; pc = 0.028, OR 3.9, EF 0.17) were also significantly increased in PsA. MICA-A9 was in linkage disequilibrium with MICB-CA-22 (D = 0.6). The association of MICA-A9 was independent of MICB-CA-22 and Cw*0602, since it was also associated in MICB-CA-22 negative (pc = 0.0015, OR 2.96, EF 0.34) and in Cw*0602 negative patients (pc = 0.034, OR 2.83, EF 0.34). TNFA and DRB1 alleles were not significantly associated with PsA. Conclusion. Cw*0602 and MICA-A9 appear to be the strongest genetic susceptibility factors for PsA. However, MICA-A9 was associated independently of Cw6. HLA-B alleles and MICB-CA22 are associated secondarily to linkage with MICA. TNFA and HLA-DRB1 were not associated with PsA susceptibility, and our data suggest that their reported association may only reflect the linkage disequilibrium with MICA-A9 among the different populations studied. (J Rheumatol 2002; 29:973-8) Key Indexing Terms:
PSORIASIS
From the University of Oviedo and Department of Immunology, Hospital Central de Asturias, Oviedo, Spain. Supported by grants PM98-0004 (Ministerio de Educación y Cultura) and FIS 00/0208. S. González, MD, PhD, Functional Biology Department, University of Oviedo; J. Martínez-Borra, BS; A. López-Vázquez, MD; S. García-Fernández, BS, Department of Immunology, Hospital Central de Asturias; J. Torre-Alonso, MD, PhD, Department of Rheumatology, Hospital Monte Naranco; C. López-Larrea, PhD, Department of Immunology, Hospital Central de Asturias. Address reprint requests to Dr. C. López-Larrea, Department of Immunology, Hospital Central de Asturias, 33006 Oviedo, Spain. E-mail: inmuno@hca.es Submitted July 24, 2001; revision accepted October 29, 2001. |